CoJourney, a Philadelphia, PA-based company which specializes in manufacturing and development of cell and gene therapies, raised $30M in Series A funding.
The round was led by Legend Holdings and supported by GL Ventures, Legend Star Investment Management and Lake Bleu Capital.
The company intends to use the funds to expand its US organization and commercial manufacturing capabilities.
Led by CEO Lijun Wang, CoJourney is a Contract Manufacturing and Development Organization (CDMO) that serves the product development and manufacturing needs of cell and gene therapy companies globally. Its services include process development, cGMP production, analytical method development, and QC testing and release for plasmids, viral vectors and mRNAs.
CoJourney has built comprehensive offerings that include banking, drug substance production and drug product filling, utilizing proprietary platform processes and extensive expertise.
The company, which has built 130,000 square foot state-of-the-art cGMP manufacturing facilities that include 500L and 2,000L disposable bioreactors for viral vectors and 30L disposable fermenters for plasmids, employs over 150 scientific and operations staff worldwide.
FinSMEs
11/07/2023